Literature DB >> 6302194

The human v-abl cellular homologue.

N Heisterkamp, J Groffen, J R Stephenson.   

Abstract

A contiguous region of cellular DNA sequence, 64 kb in length and representing overlapping cellular inserts from three independent cosmid clones, has been isolated from a representative library of human lung carcinoma DNA partially digested with MboI. Within this region of the cellular genome, v-abl homologous sequences are dispersed over a total region of around 32 kb. These sequences represent the entire v-abl human cellular homologue, are colinear with the viral v-abl transforming gene, and contain a minimum of seven intervening sequences. At least eight regions of highly repetitive DNA sequences have been shown to map in close proximity to c-abl coding sequences. In addition to the major c-abl human locus, three regions of human DNA sequence, corresponding to only portions of the v-abl gene, have been identified. Two of these have been molecularly cloned and shown to be distinct from the primary human c-abl locus. Upon transfection to rat embryo fibroblasts in culture, none of the cosmid DNAs containing v-abl homologous sequences exhibited transforming activity. These findings identify and map a single genetic locus of human DNA, c-abl, representing the complete v-abl homologue, and demonstrate the existence of additional human DNA sequences corresponding to more limited, subgenomic regions of v-abl.

Entities:  

Mesh:

Year:  1983        PMID: 6302194

Source DB:  PubMed          Journal:  J Mol Appl Genet        ISSN: 0271-6801


  18 in total

1.  Human bcr-abl gene has a lethal effect on embryogenesis.

Authors:  N Heisterkamp; G Jenster; D Kioussis; P K Pattengale; J Groffen
Journal:  Transgenic Res       Date:  1991-12       Impact factor: 2.788

2.  Recombinant tumor necrosis factor alpha and interleukin 1 alpha increase expression of c-abl protooncogene mRNA in cultured human marrow stromal cells.

Authors:  D F Andrews; J J Nemunaitis; J W Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

3.  Isolation and sequence analysis of a novel human tyrosine kinase gene.

Authors:  Q L Hao; N Heisterkamp; J Groffen
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

4.  Duplication of the bcr and gamma-glutamyl transpeptidase genes.

Authors:  N Heisterkamp; J Groffen
Journal:  Nucleic Acids Res       Date:  1988-08-25       Impact factor: 16.971

5.  The first BCR gene intron contains breakpoints in Philadelphia chromosome positive leukemia.

Authors:  N Heisterkamp; E Knoppel; J Groffen
Journal:  Nucleic Acids Res       Date:  1988-11-11       Impact factor: 16.971

6.  Identification of a human gamma-glutamyl cleaving enzyme related to, but distinct from, gamma-glutamyl transpeptidase.

Authors:  N Heisterkamp; E Rajpert-De Meyts; L Uribe; H J Forman; J Groffen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

7.  The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript.

Authors:  G Grosveld; T Verwoerd; T van Agthoven; A de Klein; K L Ramachandran; N Heisterkamp; K Stam; J Groffen
Journal:  Mol Cell Biol       Date:  1986-02       Impact factor: 4.272

8.  Breakpoints on chromosomes 9 and 22 in Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Amplification of rearranged c-abl oncogenes in CML blast crisis.

Authors:  S J Collins
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

9.  Localization of a gamma-glutamyl-transferase-related gene family on chromosome 22.

Authors:  C Morris; C Courtay; A Geurts van Kessel; J ten Hoeve; N Heisterkamp; J Groffen
Journal:  Hum Genet       Date:  1993-03       Impact factor: 4.132

10.  Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.

Authors:  J B Konopka; S M Watanabe; J W Singer; S J Collins; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.